T Pieńkowski1, C C Zielinski. 1. Department of Breast Cancer and Reconstructive Surgery, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland. tpienkowski@coi.waw.pl
Abstract
BACKGROUND: Patients with metastatic central nervous system (mCNS) disease progression from breast cancer have a poor prognosis and often develop associated neurological complications. Human epidermal growth factor receptor 2 (HER2)-positivity status increases the risk of developing mCNS disease. Trastuzumab is an mAb that targets HER2 and is known to extend survival across all stages of HER2-positive breast cancer. DESIGN: This review considers evidence from preclinical and clinical studies examining the value of continuing trastuzumab treatment in patients who develop mCNS disease. A wealth of data from clinical studies showed that trastuzumab prolonged survival in patients with mCNS disease, compared with no trastuzumab treatment, by effectively controlling their non-CNS disease. Trastuzumab has also been shown to penetrate an impaired blood-brain barrier to a limited degree, such as during radiotherapy, and intrathecal delivery of trastuzumab to the central nervous system (CNS) has shown promise. Research efforts are focussing on improving the delivery of trastuzumab to the CNS. CONCLUSION: Evidence indicates that patients with mCNS disease from HER2-positive breast cancer should continue to receive trastuzumab to control HER2-positive metastases outside the CNS and receive established therapies to control the mCNS disease.
BACKGROUND:Patients with metastatic central nervous system (mCNS) disease progression from breast cancer have a poor prognosis and often develop associated neurological complications. Human epidermal growth factor receptor 2 (HER2)-positivity status increases the risk of developing mCNS disease. Trastuzumab is an mAb that targets HER2 and is known to extend survival across all stages of HER2-positive breast cancer. DESIGN: This review considers evidence from preclinical and clinical studies examining the value of continuing trastuzumab treatment in patients who develop mCNS disease. A wealth of data from clinical studies showed that trastuzumab prolonged survival in patients with mCNS disease, compared with no trastuzumab treatment, by effectively controlling their non-CNS disease. Trastuzumab has also been shown to penetrate an impaired blood-brain barrier to a limited degree, such as during radiotherapy, and intrathecal delivery of trastuzumab to the central nervous system (CNS) has shown promise. Research efforts are focussing on improving the delivery of trastuzumab to the CNS. CONCLUSION: Evidence indicates that patients with mCNS disease from HER2-positive breast cancer should continue to receive trastuzumab to control HER2-positive metastases outside the CNS and receive established therapies to control the mCNS disease.
Authors: Pooja Murthy; Kelley M Kidwell; Anne F Schott; Sofia D Merajver; Jennifer J Griggs; Jeffrey D Smerage; Catherine H Van Poznak; Max S Wicha; Daniel F Hayes; N Lynn Henry Journal: Breast Cancer Res Treat Date: 2016-02-13 Impact factor: 4.872
Authors: Eva Negri; Alberto Zambelli; Matteo Franchi; Marta Rossi; Martina Bonifazi; Giovanni Corrao; Lorenzo Moja; Carlo Zocchetti; Carlo La Vecchia Journal: Oncologist Date: 2014-10-29
Authors: Michael C Jensen; Julie R Park; Nicholas A Vitanza; Adam J Johnson; Ashley L Wilson; Christopher Brown; Jason K Yokoyama; Annette Künkele; Cindy A Chang; Stephanie Rawlings-Rhea; Wenjun Huang; Kristy Seidel; Catherine M Albert; Navin Pinto; Juliane Gust; Laura S Finn; Jeffrey G Ojemann; Jason Wright; Rimas J Orentas; Michael Baldwin; Rebecca A Gardner Journal: Nat Med Date: 2021-07-12 Impact factor: 53.440